PORTSMOUTH, N.H., April 30,
2024 /PRNewswire/ -- Laborie Medical Technologies
Corp. (Laborie), a leading diagnostic and therapeutic medical
technology company, welcomed the inclusion of Optilume®
Urethral Drug-Coated Balloon (DCB) into the National Health Service
(NHS) Specialized Services Device Programme (SSDP) as of
April 1, 2024. This national payment
scheme ensures NHS Hospitals in England will be reimbursed for the cost of the
Optilume Urethral DCB, enabling patients to benefit from wider
access to the technology.
The SSDP, formerly the High-Cost Tariff Excluded Devices
programme (HCTED), reimburses innovative healthcare technologies
that meet specific clinical and economic criteria separately from
the core payment mechanism for medical treatments and interventions
in the NHS.
Optilume® Urethral DCB combines balloon dilation of
the urethra with the delivery of an anti-proliferative drug to
prevent the recurrence of urethral strictures. This minimally
invasive technology is expected to have a significant impact in the
urology community, offering a breakthrough treatment option for
urethral strictures that would traditionally require major surgery
or need frequent retreatment1.
"The Optilume Urethral DCB has been clinically and economically
proven through randomized clinical trials and economic
evidence2,3,4, and has been evaluated by the National
Institute for Health and Care Excellence (NICE)," said Kyle Knauf, Vice President and General Manager
of Interventional Urology at Laborie.
In November 2022, Optilume
received National Institute for Health and Care Excellence (NICE)
guideline recommendations that it is safe, effective, and cost
saving to use in clinical practice in the NHS for the treatment of
anterior urethral stricture, providing improved clinical and
economic benefits to patients versus the existing endoscopic
standard of care5.
"The inclusion as part of national funding provides all
clinically eligible patients in England access to treatment that is a more
clinically effective and durable solution while providing cost
efficiencies to the NHS," Knauf continued. "We look forward to
continuing to provide the NHS and its patients with clinically
proven technologies that preserve and restore human dignity."
About Laborie Medical Technologies
Headquartered in Portsmouth, New
Hampshire, Laborie is a global medical technology company
focused on Urology, Urogynecology, Gastroenterology, Obstetrics,
Gynecology & Neonatal Health. We manufacture and deliver
high-quality, high-impact diagnostic and therapeutic products that
help clinicians and hospitals preserve and restore patient dignity.
Clinicians and hospitals look to us as the market-leading experts
in our business segments, and we support our products with a
world-class Clinical Education & Information program. Laborie
is a portfolio company of Patricia Industries. For more information
visit www.laborie.com.
References
- Heyns CF, Steenkamp JW, De Kock ML, Whitaker P. Treatment of
male urethral strictures: is repeated dilation or internal
urethrotomy useful? J Urol. 1998 Aug;160(2):356-8. doi:
10.1016/s0022-5347(01)62894-5. PMID: 9679876.
-
VanDyke ME, Morey AF, Coutinho K, Robertson KJ, D'Anna R, Chevli K,
et al. Optilume drug-coated balloon for anterior urethral
stricture: 2-year results of the ROBUST III trial. BJUI
Compass. 2024; 5(3): 366–373.
- Mann, Rachel; Delong, Jessica; Virasoro, Ramon; Elliott,
Sean PD35-08 4 YEARS OF THE OPTILUME® DRUG COATED
BALLOON FOR RECURRENT ANTERIOR URETHRAL STRICTURES: A SUMMARY OF
ROBUST I, II AND III, Journal of Urology: April 2023 - Volume 209 - Issue Supplement 4
- Kelly L, Shore J, Wright J, Patrick C, Holmes H. Economic
evaluation of Optilume, a drug-coated balloon for recurrent
anterior male urethral stricture. BJUI Compass. 2023 Apr
10;4(4):430-436.
- Optilume for treating recurrent bulbar urethral strictures
(MTG73). ISBN: 978-1-4731-4803-1.
https://www.nice.org.uk/guidance/mtg73
View original
content:https://www.prnewswire.com/news-releases/nhs-england-reimburses-optilume-urethral-drug-coated-balloon-as-part-of-the-specialised-services-device-programme-302131518.html
SOURCE Laborie Medical Technologies